Company Summary - Sareum Holdings PLC (LSE:SAR)
1.38p
0.03p
(2.17%)
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £20.018m
NEW Explore our new and improved report for Sareum Holdings PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Discovery and development of new therapeutic drugs
| Financials - Annual Report (30/06/2011) | ||
|---|---|---|
| Turnover | £m | - |
| Pre-tax Profit | £m | -0.63 |
| EPS | p | -0.04 |
| DPS | p | - |
| Dividend Yield | % | |
| Director | Board Role |
|---|---|
| Dr. Paul Harper | Chairman |
| Dr. Tim Mitchell | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
Sareum Ltd
Broker Sentiment (0 brokers)
No current consensus recommendation available.
| Heading | Date |
|---|---|
| Notice of Results | 30/01/2012 |
| SAREUM HOLDINGS PLC : Result... | 14/12/2011 |
| Report & Accounts & Notice of AGM... | 04/11/2011 |